Search

Author/Creator Bubb, Michael

1. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. Issue 3 (30th December 2020)

Authors:
Baker, Matthew; Chaichian, Yashaar; Genovese, Mark; Derebail, Vimal; Rao, Panduranga; Chatham, Winn; Bubb, Michael; Lim, Sam; Hajian, Hooman; Gurtovaya, Oksana; Patel, Uptal; Tumlin, James
Journal:
RMD open
Issue:
Volume 6:Issue 3(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. Issue 3 (30th December 2020)

Authors:
Baker, Matthew; Chaichian, Yashaar; Genovese, Mark; Derebail, Vimal; Rao, Panduranga; Chatham, Winn; Bubb, Michael; Lim, Sam; Hajian, Hooman; Gurtovaya, Oksana; Patel, Uptal; Tumlin, James
Journal:
RMD open
Issue:
Volume 6:Issue 3(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗